House of Lords written question – answered on 10th March 2010.

Alert me about debates like this

Photo of Lord Alton of Liverpool Lord Alton of Liverpool Crossbench

To ask Her Majesty's Government how many patient-specific human pluripotent stem cells have been derived in the United Kingdom by means of (a) direct reprogramming with Yamanaka's factors to yield induced pluripotent stem cells, (b) embryonic stem cell derivation following somatic cell nuclear transfer, and (c) traditional Chinese medicine; and what is the average level of funding per individual grant or principal investigator that they have provided towards each of those approaches, via the research councils or by other means.

Photo of Lord Drayson Lord Drayson Minister of State, Ministry of Defence, Minister of State, Department for Business, Innovation and Skills, Minister of State (Ministry of Defence) (also in the Department for Business, Innovation and Skills), Minister of State (Department for Business, Innovation and Skills) (Science and Innovation) (also in the Ministry of Defence)

The Government and the research councils do not collect information on the numbers of patient-specific human pluripotent stem cells that have been derived in the UK.

The Medical Research Council (MRC) funds a wide spectrum of stem cell research supporting a range of approaches. This includes research on induced pluripotent stem (iPS) cells, some of which may involve the derivation of stem cells lines from patients to study disease using a range of technologies, including Yamanaka factors and subsequent developments. The MRC does not currently support any research which aims to derive patient-specific stem cells by human somatic cell nuclear transfer or through the use of traditional Chinese medicine.

Does this answer the above question?

Yes0 people think so

No2 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.